AI for Lung Cancer
Lung Cancer
ResearchActive
Key Facts
About Invenio Imaging
Invenio Imaging is a private, commercial-stage company pioneering real-time intraoperative histology through its NIO Laser Imaging System, which leverages Stimulated Raman Histology (SRH) technology. The company has commercialized its core hardware system and has begun integrating artificial intelligence, evidenced by its CE-marked NIO Glioma Reveal algorithm for brain tumor surgery in the EU. Invenio targets multiple surgical subspecialties, including neurosurgery, pulmonology, and urology, with the goal of improving surgical decision-making and patient outcomes by providing rapid, on-site tissue analysis without destroying the sample.
View full company profileTherapeutic Areas
Other Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| OncoStrong™ | Lamark Biotech | Preclinical |
| 15dPMJ2 | Claradele Pharmaceuticals | Research |
| SUPLEXA | Alloplex Biotherapeutics | Phase 1 |
| Oncology Digital Biomarkers | Imvaria | Development |
| Aerosolized Platinum Nanoparticles | HylaPharm | Pre-clinical |
| ENV105 | Kairos Pharma | Phase 1 |
| Liposome Program | NanoTech Pharma | Preclinical/Phase 1/2 |
| Dendritic Cell Vaccine | MegaNano BioTech | Pre-clinical |
| AI Biomarkers for Lung Cancer | BioAI Health | Unknown |
| PRDM2 Target | ARIZ Precision Medicine | Preclinical |
| ZEN-3694 | Zenith Epigenetics | Proof-of-Concept |
| TEC-001 + Keytruda | Teclison | Phase 2 |